Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).

The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.

Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.

Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.